Phio Pharmaceuticals Corp. Files 8-K on Officer/Director Changes
Ticker: PHIO · Form: 8-K · Filed: Oct 31, 2025 · CIK: 1533040
| Field | Detail |
|---|---|
| Company | Phio Pharmaceuticals Corp. (PHIO) |
| Form Type | 8-K |
| Filed Date | Oct 31, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-changes, director-changes
Related Tickers: PHIO
TL;DR
Phio Pharma (PHIO) filed an 8-K detailing leadership changes and compensation. Keep an eye on strategy shifts.
AI Summary
Phio Pharmaceuticals Corp. filed an 8-K on October 31, 2025, reporting on the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements. The filing also covers other events and financial statements/exhibits.
Why It Matters
Changes in corporate leadership and officer compensation can signal shifts in company strategy or governance, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in directors and officers, especially if numerous or unexpected, can indicate internal instability or strategic realignments that carry inherent risks.
Key Players & Entities
- Phio Pharmaceuticals Corp. (company) — Registrant
- October 31, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 411 Swedeland Road, Suite 23-1080, King of Prussia, PA 19406 (address) — Principal executive offices
FAQ
What specific officer or director positions were affected by the changes reported in this 8-K?
The filing indicates changes related to 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers,' but the specific names and roles are not detailed in the provided text.
Are there any details regarding new compensatory arrangements for officers mentioned in the filing?
The filing lists 'Compensatory Arrangements of Certain Officers' as an item, but the specifics of these arrangements are not provided in the excerpt.
What is the significance of the 'Other Events' section in this 8-K filing?
The 'Other Events' section typically covers material events that the company deems important enough to report outside of the standard categories, but the specific events are not detailed in the provided text.
Does this 8-K filing include any financial statements or exhibits?
Yes, the filing explicitly lists 'Financial Statements and Exhibits' as an item covered by this 8-K report.
What was Phio Pharmaceuticals Corp.'s former company name?
Phio Pharmaceuticals Corp.'s former company name was RXi Pharmaceuticals Corp., with a name change date of October 19, 2011.
Filing Stats: 556 words · 2 min read · ~2 pages · Grade level 9.9 · Accepted 2025-10-31 10:30:48
Key Financial Figures
- $0.0001 — h registered: Common Stock , par value $0.0001 per share PHIO The Nasdaq Capital M
Filing Documents
- phio20251030_8k.htm (8-K) — 25KB
- ex_880132.htm (EX-99.1) — 8KB
- logo.jpg (GRAPHIC) — 7KB
- 0001437749-25-032512.txt ( ) — 174KB
- phio-20251031.xsd (EX-101.SCH) — 3KB
- phio-20251031_def.xml (EX-101.DEF) — 12KB
- phio-20251031_lab.xml (EX-101.LAB) — 15KB
- phio-20251031_pre.xml (EX-101.PRE) — 12KB
- phio20251030_8k_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. On October 31, 2025, the Company issued a press release announcing the appointment of David Deming as Lead Independent Director of the Board. The full text of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by the Company on October 31, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PHIO PHARMACEUTICALS CORP. Date: October 31, 2025 By: /s/ Robert J. Bitterman Robert J. Bitterman President & Chief Executive Officer 3